Competitive Strategies Critical As EMA Decides On Kymriah And Yescarta

With Novartis’s and Kite’s CAR T-cell therapies both expected to gain recommendations for pan-EU approval this week, discounts will need to be negotiated for these new treatments to reach the markets in Europe.